ABSTRACT
BACKGROUND: Iron deficiency anemia frequently occurs in gastrectomized patients. METHODS: Serum iron levels following the ingestion of a single oral dose of 105 mg elemental iron, taken as ferrous sulfate (FeS) or ferric gluconate (FeG), have been evaluated in 20 gastrectomized patients (and 20 controls). All subjects participated on 2 different test days, 1 month apart: they took a single dose of 105 mg elemental iron as FeS or FeG after a night of fasting. Serum iron concentrations at baseline, 30, 60, 120 and 180 min after the oral dose administration were measured. RESULTS: In patients and controls receiving FeG, serum iron levels did not significantly change. After oral ingestion of FeS, patients' serum iron levels gradually increased. The increase in serum iron levels was 148 and 168% at 120 and 180 min in patients (p < 0.0001 for both evaluations), whilst in controls, it was 216% at 120 min and 234% at 180 min, i.e. significantly higher than in gastrectomized patients (p < 0.001 for both evaluations). CONCLUSIONS: In gastrectomized patients, a single oral dose of FeS shows a significant increase in iron serum concentration, albeit lower than in controls. Further studies on a larger sample of patients will be necessary to confirm these results.
Subject(s)
Ferric Compounds/pharmacokinetics , Ferrous Compounds/pharmacokinetics , Gastrectomy/adverse effects , Iron/pharmacokinetics , Absorption , Administration, Oral , Adult , Anemia, Iron-Deficiency/drug therapy , Anemia, Iron-Deficiency/etiology , Dose-Response Relationship, Drug , Female , Ferric Compounds/administration & dosage , Ferrous Compounds/administration & dosage , Follow-Up Studies , Humans , Iron/administration & dosage , Iron/blood , Male , Middle Aged , Single-Blind Method , Treatment OutcomeABSTRACT
The association between Down's syndrome (DS) and celiac disease (CD) has been confirmed by several authors. The sensitivity and specificity of antigliadin antibodies (AGAs), the clinical features of subjects with DS and CD (DS-CD+), the incidence of CD, and the results of serological and molecular class I and II HLA typing were determined in a sample of 57 Sicilian subjects with DS. Six (10.5%) and 17 subjects (29.8%) showed high levels of IgA AGAs and IgG AGAs, respectively. AGAs sensitivity and specificity were lower than in the population without DS. Ten people with DS were submitted to jejunal biopsy, and seven (12.2%) showed CD according to ESPGAN criteria. All seven patients were put on gluten-free diet, followed by rapid disappearance of symptoms. Class I and II HLA serological and molecular typing was carried out in seven DS-CD + subjects, 22 people with DS without CD (DS-CD-), five subjects with CD without DS, and 20 controls. Between DS-CD + and DS-CD- subjects, no statistically significant difference regarding serum HLA class I antigens was found. DQA1*0101 allele appears significantly in DS-CD + patients and deserves to be searched for in a larger sample to assess its meaning in the DS-CD association.
Subject(s)
Celiac Disease/complications , Down Syndrome/complications , Histocompatibility Antigens Class II/analysis , Histocompatibility Antigens Class I/analysis , Adolescent , Adult , Antibodies/blood , Celiac Disease/immunology , Child , Child, Preschool , Down Syndrome/immunology , Female , Genotype , Gliadin/immunology , HLA-DQ Antigens/genetics , Humans , Immunoglobulin A/blood , Immunoglobulin G/blood , Infant , Male , Middle Aged , SicilySubject(s)
Leukemia, Myeloid, Acute/enzymology , Adolescent , Adult , Aged , Female , Fibrinogen , Histocytochemistry , Humans , Male , Middle Aged , Tolonium ChlorideABSTRACT
It was reported a combined methodological proposal to test simultaneously activated-NBT and phagocytic index (PI) assay using zymosan particles. Such a method allowed to evaluate these two steps of the phagocytic process in the same cellular population. Comparable results were obtained performing the two methods separately.
